Free Gastroenterology CME

This course contains two courses:

• Crohn’s Disease: Therapeutic Updates, Barriers to Care, and Emerging Therapies (1 hr CME)
• Inflammatory Bowel Disease (IBD): A Global Approach to Quality Management and Barriers to Care in an Era of Resource Consciousness(1.25 hr CME)
• In order to get credit from ScientiaCME, you must first establish a username and password.

Target Audience:

Healthcare professionals specializing in colon and rectal surgery, family medicine, internal medicine, gastroenterology, oncology, pain management, palliative care, primary care, proctology, and other clinicians who treat patients suffering from gastrointestinal disorders.

Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.

Target Audience:

Healthcare professionals including: medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.

Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease (CD), the former of which exclusively affects the colon and rectum. UC occurs more frequently than CD, with an incidence of 1.2 to 20.3 cases per 100,000 persons per year and a prevalence of 7.6 to 246.0 cases per 100,000 per year, as compared to 0.03 to 15.6 and 3.6 to 214.0 per 100,000 for CD. Risk factors include characteristics common in westernized environments and lifestyles, including smoking, diets high in fat and sugar, medication use, stress, and high socioeconomic status.

Target Audience:

HCPs specializing in: gastroenterology, internal medicine; nurse practitioners, physician assistants, and pharmacists who specialize in gastroenterology; and those who otherwise commonly care for or clinically encounter patients with UC.

By the end of the session the participant will be able to:

• Describe the burden of disease UC represents to patients.
• Identify the present treatment options currently available for management of UC and apply them to patient cases using evidence-based medicine.
• Identify new and emerging therapies for the treatment of UC.
• Evaluate a treatment plan for a specific patient based on severity of UC to optimize safety, efficacy, and cost-efficacy, suggesting modifications for improvement.

Activity Description / Statement of Need:

Clostridioides difficile (formerly known as Clostridium difficile) is a gram-positive obligate anaerobe that produces exotoxins in the gastrointestinal (GI) tract resulting in watery, loose stool, abdominal pain, and nausea. The U.S. incidence of Clostridioides difficile infection (CDI) is about half a million people, with 28% community-acquired, 37% healthcare-associated, and 36% associated with long-term care facilities. Additionally, CDI has incurred one billion dollars in costs to the U.S. healthcare system. Antibiotic exposure causes changes to the GI microflora and increases the risk of developing CDI, which is especially seen in carbapenems, third-/fourth- generation cephalosporins, clindamycin, and fluoroquinolone use. Other risk factors include acid suppressive therapy; age; prolonged hospitalizations or other recent healthcare exposure; recent tube feeding or GI surgery; and immunocompromised states, including recent chemotherapy.

Target Audience:

HCPs including: infectious diseases physicians, gastroenterologists, hospitalists, and intensivists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CDI. 

Activity Description / Statement of Need:

In this online, self-learning activity:

Irritable bowel syndrome (IBS) is among the most common disorders seen by primary care as well as gastroenterology specialty clinics. Patients with IBS usually present with chronic abdominal pain and altered bowel habit, in the absence of any other disease to cause these sorts of symptoms. The disorder is associated with annual healthcare expenditures of $20 billion and significant costs in lost work productivity and health-related quality-of-life.

Although not uncommon, there is still much that is unknown about IBS-C, and its diagnosis has largely remained dependent on symptom-based criteria with their share of limitations.

This activity has been designed to update HCPs’ knowledge of IBS-C and to improve their competence and performance in treating it.

Target Audience:

The following HCPs: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in gastroenterology; and any other HCPs with an interest in or who clinically encounter patients with IBS-C.

Activity Description / Statement of Need:
In this online, self-learning activity:

Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Systemic therapy is the mainstay of treatment for advanced and metastatic disease. There is a widening number of treatment options for GC and GEJC with approved and investigational agents. This learning activity has therefore been designed to bring HCPs’ knowledge of the rationale behind treatment of GC and GEJC up to date and to enhance their competence and performance in the management of it.

Target Audience:
HCPs including: Medical oncologists, pathologists, physician assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

Activity Description / Statement of Need:

In this online, self-learning activity:

Non-alcoholic steatohepatitis (NASH) is a form of non-alcoholic fatty liver disease (NAFLD) characterized by steatosis, with the accumulation of fat in the liver in excess of five percent of the liver’s weight, together with hepatic inflammation in the presence or absence of fibrosis. Risk factors for NASH include a number of comorbid metabolic diseases and disorders, including metabolic syndrome, obesity, type 2 diabetes, hypertension, and dyslipidemia. The prevalence of NASH is estimated to be 1.5%-6.45% of the U.S. population, and prevalence of NASH among NAFLD patients to be 59.1% globally.

Target Audience:

The following HCPs in: Gastroenterology, hepatology, and endocrinology; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with NAFLD.

Activity Description / Statement of Need:

In this online, self-learning activity:

Irritable bowel syndrome (IBS) is among the most common disorders seen by primary care as well as gastroenterology specialty clinics. Patients with IBS usually present with chronic abdominal pain and altered bowel habit, in the absence of any other disease to cause these sorts of symptoms. While the precise pathophysiology is still an area of active investigation, it appears to include a neuro-enteric disconnect, leading to intestinal somato-visceral and motor dysfunction. Genetic, immune function, microbiome, psychological, and environmental factors may also predispose patients to develop of IBS. Its prevalence varies according to country and the criteria used to define it. In North America and Europe, it has a 10-15% prevalence, and it varies by country. In the U.S. and Canada, IBS symptoms are 1.5 to 2 times more prevalent among women. Women commonly report abdominal pain and constipation while men report diarrhea. The disorder is associated with annual healthcare expenditures of $20 billion and significant costs in lost work productivity and health-related quality-of-life. 

Target Audience:

The following HCPs: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in gastroenterology and internal medicine; and any other HCPs with an interest in or who clinically encounter patients with IBS-C.